ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2021
Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Effect of modified Mediterranean diet supplemented with partial enteral nutrition in post-surgical patients with Crohn's disease: a pilot clinical trial.The British journal of nutrition · 2026Trial
- Declining rates of surgery in pediatric-onset inflammatory bowel disease: a Swedish nationwide register-based cohort study 2002-2022.Journal of Crohn's & colitis · 2026Article
- All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study.Journal of Crohn's & colitis · 2026Article
- Machine learning prediction of increased healthcare utilization in colectomy for inflammatory bowel disease.International journal of colorectal disease · 2026Article
- Inflammatory bowel disease and extracellular matrix: when victim becomes double agent.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Prediction of endoscopic postoperative recurrence in Crohn's disease: a nationwide multicenter real-world cohort from China.Gastroenterology report · 2026Article
- A narrative review of sex-related differences in inflammatory bowel disease-associated cardiovascular and thrombotic risk: epidemiology, mechanisms, and prevention strategies.Translational gastroenterology and hepatology · 2026Review
- Review
- Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region.Pharmacological reports : PR · 2025Observational
- Pregnancy With a Stoma is Feasible, Though Associated With Manageable Complications.Inflammatory bowel diseases · 2025Article
- Nationwide study on clinical impact of early tumor necrosis factor-α inhibitors following first intestinal resection in biologics-naïve Crohn's disease patients.Scientific reports · 2025Article
- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn's Disease in the Biologic Era.Inflammatory bowel diseases · 2025Article
- Anastomosis after Bowel Resection for Crohn's Disease: State of the Art Review.Clinics in colon and rectal surgery · 2025Review
- Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2024Article
- Perceptions, behaviours and barriers towards exercise practices in inflammatory bowel disease.PloS one · 2024Article
- Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease.World journal of gastroenterology · 2023Review
- Selenized Polymer-Lipid Hybrid Nanoparticles for Oral Delivery of Tripterine with Ameliorative Oral Anti-Enteritis Activity and Bioavailability.Pharmaceutics · 2023Article
- Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania.Medicina (Kaunas, Lithuania) · 2023Article
- IBD barriers across the continents - East Asia.Therapeutic advances in gastroenterology · 2023Review
- Editorial: Exploring the interplay between clinical and non-clinical outcomes for children and adults with inflammatory bowel disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedical therapy for inflammatory bowel disease (IBD) has markedly advanced since the introduction of biologic therapeutics, although surgery remains an important therapeutic strategy for both Crohn's disease (CD) and ulcerative colitis (UC). This study evaluated how rates of bowel resection surgery and post-operative mortality for IBD have changed over the last decade in the era of biologic therapies.
methodsThe Nationwide Readmission Database (NRD) was queried for patients with IBD (based on ICD-9 and -10 diagnosis and procedure codes) who were hospitalized between 2010 and 2017. Longitudinal trends in bowel resection surgery, urgent surgery, and post-operative mortality were analyzed.
resultsDuring the 8-year period, a total of 1795,266 IBD-related hospitalizations (1,072,110 with CD and 723,156 with UC) were evaluated. There was an increase in the annual number of IBD patients hospitalized, but a statistically significant decrease in the proportion of IBD patients undergoing surgery, from 10 to 8.8% (p < 0.001) for CD and 7.7 to 7.5% (p < 0.001) for UC. From 2014 through 2017, the proportion of urgent surgeries remained stable around 25% (p = 0.16) for CD and decreased from 21 to 14% (p < 0.001) for UC. For CD, the rate of post-operative 30-day mortality varied between 1.2 and 1.6% and for UC decreased from 5.8 to 2.3% (p < 0.001).
conclusionsAnalysis of a nationwide dataset from 2010 to 2017 determined that despite an increase in total admissions for IBD, a smaller proportion of hospitalized patients underwent surgery. A greater proportion of surgeries for UC were performed on an elective basis, and overall the rates of post-operative mortality for CD and UC decreased. The growth of biologic medical therapy during the study period highlights a probable contributing factor for the observed changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.